NCT04589845 2026-03-06Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyHoffmann-La RochePhase 2 Recruiting920 enrolled 1 FDA
NCT03141684 2025-10-08Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part SarcomaNational Cancer Institute (NCI)Phase 2 Active not recruiting63 enrolled 1 FDA